Skip to main content
. 2024 Dec 9;13(23):7488. doi: 10.3390/jcm13237488

Table 4.

Summary of results with weighted averages.

Outcome Weighted Average
Partial tumor response 40%
Stable disease 50%
Progressive disease 10%
Hearing improvement 36%
Stable hearing 46%
Hearing Loss 18%
Severe adverse effects (Grade 3/4) 13%
Other adverse effects 69%
No adverse effects 18%